临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1215011-08-7

PCLX-001 (DDD86481)

CAS号:1215011-08-7
分子式: C24H30Cl2N6O2S 分子量: 537.51
产品形式: free base
研发状态: Recruiting
研发用途: B-cell Non Hodgkin Lymphoma; Advanced Solid Tumor
研究机构: Pacylex Pharmaceuticals
研发日期: September 14 2021
研发阶段: Phase 1
PCLX-001 (DDD86481) is an orally active dual N-myristoyltransferase (NMT) inhibitor. It inhibits NMT1 and NMT2 with IC50 of 5 nM and 8 nM, respectively, in vitro. PCLX-001 inhibits early B-cell receptor (BCR) signalling, which can be used in B-cell malignancy research.

CAS: 121268-17-5

Alendronate sodium trihydrate

中文名称:阿仑膦酸钠,三水合物
CAS号:121268-17-5
分子式: C4H13NO7P2.3H2O.Na 分子量: 326.13
产品形式: Sodium Salt
研发状态: Not yet recruiting
研发用途: Postmenopausal Osteoporosis
研究机构: Peking University Third Hospital
研发日期: January 1 2023
研发阶段: Phase 4
Alendronate sodium trihydrate (G-704650, MK-217), a nitrogen-containing bisphosphonate, is a potent inhibitor of bone resorption used for the treatment and prevention of osteoporosis.

CAS: 1211443-80-9

Ribociclib hydrochloride

中文名称:瑞博西尼盐酸盐
CAS号:1211443-80-9
分子式: C23H31ClN8O 分子量: 471.00
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV Glioma
研究机构: Nationwide Children''s Hospital; Novartis
研发日期: May 30 2024
研发阶段: Phase 2
Ribociclib (LEE011) hydrochloride is a highly specific dual inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM, respectively.

CAS: 1211441-98-3

Ribociclib (LEE011)

中文名称:瑞博西尼
CAS号:1211441-98-3
分子式: C23H30N8O 分子量: 434.54
产品形式: free base
研发状态: Not yet recruiting
研发用途: High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV Glioma
研究机构: Nationwide Children''s Hospital; Novartis
研发日期: May 30 2024
研发阶段: Phase 2
Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.

CAS: 1210344-83-4

Ertugliflozin L-pyroglutamic acid

中文名称:埃格列净 L-焦谷氨酸盐
CAS号:1210344-83-4
分子式: C27H32ClNO10 分子量: 566.00
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Diabetes Mellitus; Diabetic Kidney Disease; Hypertension
研究机构: Amsterdam UMC location VUmc; Merck Sharp & Dohme LLC; University of Colorado Denver
研发日期: June 1 2023
研发阶段: Phase 4
Ertugliflozin (MK-8835, PF-04971729) L-pyroglutamic acid is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2) with IC50 of 0.877 nM for h-SGLT2. Ertugliflozin has the potential for the treatment of type 2 diabetes mellitus.

CAS: 121032-29-9

Nelarabine

中文名称:奈拉滨
CAS号:121032-29-9
分子式: C11H15N5O5 分子量: 297.27
产品形式: free base
研发状态: Recruiting
研发用途: T-cell Adult Acute Lymphoblastic Leukemia
研究机构: Assistance Publique - Hôpitaux de Paris
研发日期: Dec-15
研发阶段: Phase 2
Nelarabine (506U78,Arranon) is a purine nucleoside analog and DNA synthesis inhibitor with IC50 from 0.067-2.15 μM in tumor cells.